Results from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR plus triplenegative breast cancer (TNBC) Meeting Abstract

  

Authors:	Traina, T. A.; Miller, K.; Yardley, D. A.; O'Shaughnessy, J.; Cortes, J.; Awada, A.; Kelly, C. M.; Trudeau, M. E.; Schmid, P.; Gianni, L.; Garcia-Estevez, L.; Nanda, R.; Ademuyiwa, F. O.; Chan, S.; Steinberg, J. L.; Blaney, M. E.; Tudor, I. C.; Uppal, H.; Peterson, A. C.; Hudis, C. A.
Abstract Title:	Results from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR plus triplenegative breast cancer (TNBC)
Meeting Title:	51st Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title:	Journal of Clinical Oncology
Volume:	33
Issue:	15 Suppl.
Meeting Dates:	2015 May 29-Jun 2
Meeting Location:	Chicago, IL
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2015-05-20
Language:	English
ACCESSION:	WOS:000358036900035
PROVIDER:	wos
DOI:	10.1200/JCO.2015.33.15_suppl.1003
Notes:	Meeting Abstract: 1003 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/80612